FDA approves first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU October 12, 2022
KEYTRUDA® Receives Four New Approvals in Japan, Including in High-Risk Early-Stage TNBC October 5, 2022
FDA approved Lytgobi (futibatinib) for adults with advanced intrahepatic cholangiocarcinoma (iCCA) who have FGFR2 gene fusions or other rearrangements October 5, 2022
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib September 28, 2022
Trodelvy® Significantly Improved OS In Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients In TROPiCS-02 Study September 13, 2022
Kisqali® Adds One More Year Of Survival Benefit For Broadest Set Of Patients, Including Those With Aggressive HR+/HER2- Advanced Breast Cancer September 13, 2022
Enhertu continues to demonstrate clinically meaningful tumour response in patients with HER2-mutant mNSCLC September 13, 2022
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence June 14, 2022
Modi-1 Ph 1/2 trial open for recruitment in patients with TNBC, ovarian cancer, head and neck cancer, and RCC April 12, 2022
Incyclix Bio Announces $30M Series B Financing to Support Clinical Development of INX-315 April 1, 2022
